Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipratropium bromide Respimat vs Atrovent in COPD
NCT02177344Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 1998
- Primary completion
- Oct 1999
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ipratropium bromide in chronic obstructive pulmonary disease (COPD), sponsored by Boehringer Ingelheim. Started Aug 1998; status: completed.
02
Drugs
ipratropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02177344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02177344.